-
Je něco špatně v tomto záznamu ?
Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial
JA. Boatman, JV. Baker, S. Emery, H. Furrer, DM. Mushatt, D. Sedláček, JD. Lundgren, JD. Neaton, INSIGHT START Study Group,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
MC_UU_12023/23
Medical Research Council - United Kingdom
UM1 AI068641
NIAID NIH HHS - United States
UM1 AI120197
NIAID NIH HHS - United States
Department of Health - United Kingdom
NLK
Freely Accessible Journals
od 1999
Freely Accessible Science Journals
od 1988 do Před 12 měsíci
- MeSH
- CD4-pozitivní T-lymfocyty účinky léků MeSH
- dospělí MeSH
- HIV infekce farmakoterapie MeSH
- látky proti HIV terapeutické užití MeSH
- lidé MeSH
- logistické modely MeSH
- neúspěšná terapie MeSH
- počet CD4 lymfocytů * statistika a číselné údaje MeSH
- rizikové faktory MeSH
- sexuální faktory MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: Low CD4 recovery among HIV-positive individuals who achieve virologic suppression is common but has not been studied among individuals initiating treatment at CD4 counts of >500 cells/mm. SETTING: United States, Africa, Asia, Europe and Israel, Australia, Latin America. METHODS: Among participants randomized to immediate antiretroviral therapy (ART) in the Strategic Timing of AntiRetroviral Therapy trial, low CD4 recovery was defined as a CD4 increase of <50 cells/mm from baseline after 8 months despite viral load of ≤200 copies/mL. Risk factors for low recovery were investigated with logistic regression. RESULTS: Low CD4 recovery was observed in 39.7% of participants. Male sex [odds ratio (OR), 1.53; P = 0.007], lower screening CD4 cell counts (OR, 1.09 per 100 fewer cells/mm; P = 0.004), higher baseline CD8 cell counts (OR, 1.05 per 100 more cells/mm; P < 0.001), and lower HIV RNA levels (OR, 1.93 per log10 decrease; P < 0.001) were associated with low CD4 recovery. D-dimer had a quadratic association with low CD4 recovery, with lowest odds occurring at 0.32 μg/mL. At lower HIV RNA levels, the odds of low CD4 recovery were elevated across the levels of screening CD4 count; but at higher HIV RNA levels, the odds of low CD4 recovery were higher among those with lower vs. higher screening CD4. CONCLUSIONS: Low CD4 recovery is frequent among participants starting ART at high CD4 counts. Risk factors include male sex, lower screening CD4 cell counts, higher CD8 cell counts, and lower HIV RNA levels. More follow-up is required to determine the impact of low CD4 recovery on clinical outcomes.
Bern University Hospital University of Bern Bern Switzerland
Charles University Hospital Plzen Czech Republic
Tulane University New Orleans LA
University of Copenhagen Denmark
University of Minnesota Minneapolis MN
University of Minnesota Minneapolis MN Hennepin Healthcare Research Institute Minneapolis MN
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045037
- 003
- CZ-PrNML
- 005
- 20200114153726.0
- 007
- ta
- 008
- 200109s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/QAI.0000000000001967 $2 doi
- 035 __
- $a (PubMed)30664075
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Boatman, Jeffrey A $u University of Minnesota, Minneapolis, MN.
- 245 10
- $a Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial / $c JA. Boatman, JV. Baker, S. Emery, H. Furrer, DM. Mushatt, D. Sedláček, JD. Lundgren, JD. Neaton, INSIGHT START Study Group,
- 520 9_
- $a BACKGROUND: Low CD4 recovery among HIV-positive individuals who achieve virologic suppression is common but has not been studied among individuals initiating treatment at CD4 counts of >500 cells/mm. SETTING: United States, Africa, Asia, Europe and Israel, Australia, Latin America. METHODS: Among participants randomized to immediate antiretroviral therapy (ART) in the Strategic Timing of AntiRetroviral Therapy trial, low CD4 recovery was defined as a CD4 increase of <50 cells/mm from baseline after 8 months despite viral load of ≤200 copies/mL. Risk factors for low recovery were investigated with logistic regression. RESULTS: Low CD4 recovery was observed in 39.7% of participants. Male sex [odds ratio (OR), 1.53; P = 0.007], lower screening CD4 cell counts (OR, 1.09 per 100 fewer cells/mm; P = 0.004), higher baseline CD8 cell counts (OR, 1.05 per 100 more cells/mm; P < 0.001), and lower HIV RNA levels (OR, 1.93 per log10 decrease; P < 0.001) were associated with low CD4 recovery. D-dimer had a quadratic association with low CD4 recovery, with lowest odds occurring at 0.32 μg/mL. At lower HIV RNA levels, the odds of low CD4 recovery were elevated across the levels of screening CD4 count; but at higher HIV RNA levels, the odds of low CD4 recovery were higher among those with lower vs. higher screening CD4. CONCLUSIONS: Low CD4 recovery is frequent among participants starting ART at high CD4 counts. Risk factors include male sex, lower screening CD4 cell counts, higher CD8 cell counts, and lower HIV RNA levels. More follow-up is required to determine the impact of low CD4 recovery on clinical outcomes.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a látky proti HIV $x terapeutické užití $7 D019380
- 650 12
- $a počet CD4 lymfocytů $x statistika a číselné údaje $7 D018791
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x účinky léků $7 D015496
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HIV infekce $x farmakoterapie $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a logistické modely $7 D016015
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a sexuální faktory $7 D012737
- 650 _2
- $a neúspěšná terapie $7 D017211
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Baker, Jason V $u University of Minnesota, Minneapolis, MN. Hennepin Healthcare Research Institute, Minneapolis, MN.
- 700 1_
- $a Emery, Sean $u University of New South Wales, Sydney, Australia.
- 700 1_
- $a Furrer, Hansjakob $u Bern University Hospital, University of Bern, Bern, Switzerland.
- 700 1_
- $a Mushatt, David M $u Tulane University, New Orleans, LA.
- 700 1_
- $a Sedláček, Dalibor $u Charles University Hospital, Plzen, Czech Republic.
- 700 1_
- $a Lundgren, Jens D $u University of Copenhagen, Denmark.
- 700 1_
- $a Neaton, James D $u University of Minnesota, Minneapolis, MN.
- 710 2_
- $a INSIGHT START Study Group
- 773 0_
- $w MED00005434 $t Journal of acquired immune deficiency syndromes (1999) $x 1944-7884 $g Roč. 81, č. 1 (2019), s. 10-17
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30664075 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200114154059 $b ABA008
- 999 __
- $a ok $b bmc $g 1483306 $s 1083710
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 81 $c 1 $d 10-17 $e 20190501 $i 1944-7884 $m Journal of acquired immune deficiency syndromes $n J Acquir Immune Defic Syndr $x MED00005434
- GRA __
- $a MC_UU_12023/23 $p Medical Research Council $2 United Kingdom
- GRA __
- $a UM1 AI068641 $p NIAID NIH HHS $2 United States
- GRA __
- $a UM1 AI120197 $p NIAID NIH HHS $2 United States
- GRA __
- $p Department of Health $2 United Kingdom
- LZP __
- $a Pubmed-20200109
